Jeff Paley

KellBenx, Inc. develops non-invasive prenatal diagnostics for analyzing genetic disorders and to determine a woman's risk of preterm delivery. The company was founded in 2010 and is headquartered in Great River, NY.

Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ.

Kalytera Therapeutics, Inc. develops non-psychoactive cannabinoid and endocannabinoid-like medicines that address the large unmet market needs. Its preclinical studies support the continued investigation of Kalytera drug candidates in a range of conditions, including bone fracture healing, osteogenesis imperfecta, osteoporosis, and osteoporosis in Prader-Willi syndrome. The company was founded by Seth Yakatan and David Stefansky in 2014 and is headquartered in Manhattan Beach, CA.